The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: A pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 11-12, 2014, Pages 1302-1312

  Chang, L ^a   Lembo, A J ^b   Lavins, B J ^c   Shiff, S J ^d   Hao, X ^c   Chickering, J G ^c   Jia, X D ^d   Currie, M G ^c   Kurtz, C B ^c   Johnston, J M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c IRONWOOD PHARMACEUTICALS INC   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINACLOTIDE; PEPTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; ADULT; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; CHRONIC DISEASE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT SATISFACTION; PEPTIDES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84909581080     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12985     Document Type: Article

References (44)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9.
2. Suares NC, Ford AC. Diagnosis and treatment of irritable bowel syndrome. Discov Med 2011; 11: 425-33.
3. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5.
4. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 1360-8.
5. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007; 26: 227-36.
6. Sun SX, Dibonaventura M, Purayidathil FW, Wagner JS, Dabbous O, Mody R. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 2011; 56 : 2688-95.
7. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002; 97: 1986-93.
8. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010; 31: 938-49.
9. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009; 136: 741-54.
10. Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ 2013; 17: 148-58.
11. Sethi S, Mikami S, Leclair J, et al. Inpatient burden of constipation in the United States: an analysis of national trends in the United States from 1997 to 2010. Am J Gastroenterol 2014; 109: 250-6.
12. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007; 26: 237-48.
13. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
14. Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144: 218-38.
15. Bharucha AE, Locke GR, Zinsmeister AR, et al. Differences between painless and painful constipation among community women. Am J Gastroenterol 2006; 101: 604-12.
16. Drossman DA, Morris C, Hu Y, et al. Further characterization of painful constipation (PC): clinical features over one year and comparison with IBS. J Clin Gastroenterol 2008; 42 : 1080-8.
17. Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil 2012; 24: 791-801.
18. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599-608.
19. Bharucha AE, Dorn SD, Lembo A, Pressman A. American gastroenterological association medical position statement on constipation. Gastroenterology 2013; 144: 211-7.
20. Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can J Gastroenterol 2011; 25: 36-40.
21. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
22. Frissora CL. Diagnosis, treatment, and management of irritable bowel syndrome with constipation and chronic constipation. Med Gen Med 2005; 7: 71.
23. Bassotti G, Carlani E, Baldón M, Gullà N, Morozzi B, Villanacci V. Painful constipation: a neglected entity? Rev Esp Enferm Dig 2011; 103: 25-8.
24. Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013; 145: 749-57; quiz e13-4.
25. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39: 312-21.
26. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol 2014; 109: 876-84.
27. Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010; 105: 2228-34.
28. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005; 100 (Suppl. 1): S5-21.
29. Talley NJ. Differentiating functional constipation from constipationpredominant irritable bowel syndrome: management implications. Rev Gastroenterol Disord 2005; 5: 1-9.
30. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005; 7: 264-71.
31. Lacy BE, Weiser K, De LR. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2009; 2: 221-38.
32. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-43.
33. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527-36.
34. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the ef ficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-25.
35. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate ef ficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
36. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Functional bowel disorders and functional abdominal pain. In: Drossman, DA, ed. ROME II: The Functional Gastrointestinal Disorders Degnon Associates: McLean, Virginia, USA, 2000; 360-91.
37. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
38. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 540-51.
39. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012; 107: 286-95.
40. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome. Gastroenterology 2010; 139: 1877-86.
41. Rao S. Phase 3 clinical trial of linaclotide in patients with IBS-C demonstrates significant improvements in abdominal pain and bowel symptoms. Neurogastroenterol Motil 2011; 23: 2.
42. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29-34.
43. Basilisco G, Coletta M. Chronic constipation: a critical review. Dig Liver Dis 2013; 45 : 886-93.
44. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23.